Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.78
CRTX's Cash to Debt is ranked higher than
55% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CRTX: 0.78 )
CRTX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.78

Equity to Asset 0.48
CRTX's Equity to Asset is ranked higher than
60% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRTX: 0.48 )
CRTX' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.87
Current: 0.48

-0.77
0.87
F-Score: 6
Z-Score: 1.42
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -23.55
CRTX's Operating margin (%) is ranked higher than
76% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. CRTX: -23.55 )
CRTX' s 10-Year Operating margin (%) Range
Min: -1979.24   Max: 16.38
Current: -23.55

-1979.24
16.38
Net-margin (%) -10.24
CRTX's Net-margin (%) is ranked higher than
77% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. CRTX: -10.24 )
CRTX' s 10-Year Net-margin (%) Range
Min: -1969.64   Max: 13.86
Current: -10.24

-1969.64
13.86
ROE (%) -7.15
CRTX's ROE (%) is ranked higher than
77% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. CRTX: -7.15 )
CRTX' s 10-Year ROE (%) Range
Min: -97.75   Max: 30.56
Current: -7.15

-97.75
30.56
ROA (%) -3.22
CRTX's ROA (%) is ranked higher than
80% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CRTX: -3.22 )
CRTX' s 10-Year ROA (%) Range
Min: -83.84   Max: 12.87
Current: -3.22

-83.84
12.87
ROC (Joel Greenblatt) (%) -2086.87
CRTX's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. CRTX: -2086.87 )
CRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2118.71   Max: 1187.49
Current: -2086.87

-2118.71
1187.49
Revenue Growth (%) -8.70
CRTX's Revenue Growth (%) is ranked higher than
68% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. CRTX: -8.70 )
CRTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 57
Current: -8.7

0
57
» CRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CRTX Guru Trades in Q1 2013

Jim Simons 258,829 sh (+4.06%)
» More
Q2 2013

CRTX Guru Trades in Q2 2013

Jim Simons 310,529 sh (+19.97%)
» More
Q3 2013

CRTX Guru Trades in Q3 2013

Mario Gabelli 20,400 sh (New)
Jim Simons 311,629 sh (+0.35%)
» More
Q4 2013

CRTX Guru Trades in Q4 2013

Jim Simons 380,774 sh (+22.19%)
Mario Gabelli 20,400 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRTX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-09-30 New Buy$7.99 - $9.81 $ 9.495%20400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.10
CRTX's P/E(ttm) is ranked higher than
65% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. CRTX: 29.10 )
CRTX' s 10-Year P/E(ttm) Range
Min: 2.56   Max: 809.33
Current: 29.1

2.56
809.33
P/B 1.37
CRTX's P/B is ranked higher than
93% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CRTX: 1.37 )
CRTX' s 10-Year P/B Range
Min: 0.31   Max: 14.07
Current: 1.37

0.31
14.07
P/S 1.71
CRTX's P/S is ranked higher than
92% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. CRTX: 1.71 )
CRTX' s 10-Year P/S Range
Min: 0.23   Max: 48.56
Current: 1.71

0.23
48.56
PFCF 6.78
CRTX's PFCF is ranked higher than
95% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. CRTX: 6.78 )
CRTX' s 10-Year PFCF Range
Min: 2.37   Max: 99999999.99
Current: 6.78

2.37
99999999.99
EV-to-EBIT 27.46
CRTX's EV-to-EBIT is ranked lower than
58% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CRTX: 27.46 )
CRTX' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 52.5
Current: 27.46

0.3
52.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
CRTX's Price/DCF (Projected) is ranked higher than
95% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. CRTX: 0.90 )
CRTX' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 1.66
Current: 0.9

0.48
1.66
Price/Median PS Value 1.00
CRTX's Price/Median PS Value is ranked higher than
65% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CRTX: 1.00 )
CRTX' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 28.81
Current: 1

0.15
28.81
Earnings Yield (Greenblatt) 3.60
CRTX's Earnings Yield (Greenblatt) is ranked higher than
54% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CRTX: 3.60 )
CRTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 396.1
Current: 3.6

1.9
396.1
Forward Rate of Return (Yacktman) -3.09
CRTX's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. CRTX: -3.09 )
CRTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1518.6   Max: -3.6
Current: -3.09

-1518.6
-3.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUJ1.Germany
Cornerstone Therapeutics, Inc., a Delaware Corporation founded in 2000. The Company is a specialty pharmaceutical company which commercializes products for the hospital and adjacent specialty markets. Its currently marketed and approved products include: CARDENE I.V., an FDA-approved premixed injection indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable; CUROSURF, an FDA-approved natural lung surfactant indicated for the treatment of Respiratory Distress Syndrome, or RDS, in premature infants; ZYFLO, the only FDA-approved leukotriene synthesis inhibitor indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older; BETHKIS, an inhaled tobramycin-based product indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa, or PA, approved by the FDA in October 2012; Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension, or HP/CP ER Suspension, an FDA approved antitussive/antihistamine combination product that is a generic equivalent for the product currently sold under the Tussionex Pennkinetic,or Tussionex, brand name in the United States. Its customers consist of drug wholesalers, retail drug stores, mass merchandisers and grocery store pharmacies in the United States. It primarily sell products directly to drug wholesalers, which in turn distribute the products to retail drug stores, hospitals, mass merchandisers and grocery store pharmacies. It currently outsources the manufacturing of all of its commercially available products and the formulation development of its product candidates for use in clinical trials to third parties. It have U.S. and/or foreign trademark registrations and filings for certain of its corporate names, products (including CARDENE I.V., ZYFLO CR and ZYFLO) and product candidates (including RETAVASE and LIXAR). CUROSURF and BETHKIS are owned by Chiesi and are licensed to it for sales and marketing purposes in the United States. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. The Company, its contract manufacturers and packagers, and its products and product candidates are subject to the Controlled Substances Act and DEA regulations thereunder.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide